Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Names Dr. Robert S. Epstein to its Board of Directors

Published: Monday, December 03, 2012
Last Updated: Monday, December 03, 2012
Bookmark and Share
Dr. Epstein has worked in public health and academia before joining the private sector.

Illumina, Inc. has announced that Dr. Robert S. Epstein, M.D., has joined the company's Board of Directors. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector.

Previously, from 2010 to 2012, Dr. Epstein was Chief R&D Officer and President of Medco-UBC, a 2,400 person global research organization focused on conducting personalized medicine, health economics, drug safety, outcomes, and comparative effectiveness research on behalf of the biopharmaceutical, medical device, and diagnostics industries.

Prior to this role, Dr. Epstein was Medco's Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting.

In addition, Dr. Epstein is the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life.

Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA.

"We are delighted to welcome Rob to the Illumina Board, and excited by the prospect of working with this dynamic leader to advance personalized medicine," said Jay Flatley, Illumina's President and CEO.

Flatley continued, "Benefiting from Rob's perspective and expertise, at this critical time when scientific and technological advances in genetic research and biomedicine are beginning to transform healthcare, will be invaluable as Illumina pursues its clinical diagnostic growth strategy."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Applauds FDA’s Issuance of Draft Guidances
Company has supported the FDA in their efforts to provide a flexible and streamlined approach to the oversight of NGS diagnostic test.
Friday, July 08, 2016
Illumina Invests In New Venture Fund
Illumina will commit $100M over 10 years to drive genomic technology development.
Friday, April 15, 2016
Illumina Sues Oxford Nanopore for Patent Infringement
Illumina, Inc. has announced that the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).
Wednesday, February 24, 2016
Illumina Signs Multiple Biobank Deals
Company has signed four deals to advance personalized medicine and improve health care.
Tuesday, February 09, 2016
Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Bio-Rad, Illumina Partner
Scalable, high-throughput platform to offer unprecedented insight into gene expression of individual cells.
Tuesday, January 12, 2016
Illumina Files Patent Infringement Suit Against Premaitha
Patent infringement suit filed in the United Kingdom against Premaitha Health plc for infringement of NIPT patents.
Monday, March 16, 2015
Science for Life Laboratory Joins the Illumina Genome Network
First European Genome Network partner plans large scale population sequencing program.
Monday, February 24, 2014
Illumina to Provide NGS Technologies to Quest Diagnostics
The multi-year licensing agreement is related to the use of Illumina's next-generation sequencing technology for clinical laboratory testing.
Thursday, January 09, 2014
Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2012
Revenue of $309 million, a 24% increase compared to $250 million in the fourth quarter of 2011.
Tuesday, January 29, 2013
Caris Life Sciences Selects Illumina’s MiSeq® System
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.
Friday, November 09, 2012
Illumina and Wellcome Trust Sanger Institute Announce Completed Genome for Endangered Tasmanian Devil
Uncovering mutations found in deadly transmissible cancer could help conservation efforts.
Monday, September 20, 2010
Genomic Medicine Institute Adds Seven Additional Illumina Genome Analyzers
Acquisition expands the capacity of GMI’s recently established Asian Genome Center to 10 Illumina sequencing systems.
Thursday, July 23, 2009
Illumina Announces Personal Genome Sequencing Service
Company has unveiled a service program to provide high-quality personal genome sequencing for consumers.
Friday, June 12, 2009
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!